Starting TRT in Your 40s: Why a Low Number Isn’t the Whole Story

Viewing This Video Is A Member Exclusive Feature

But you don’t need membership to get Dr. O’Connor’s insight on this topic, it’s in the summary, key takeaways, and related drugs and conditions below.

Want to watch the full video? Join the Health Portal Today.

Join Now

Already a member? Sign In

Timeline

00:00

A question about starting testosterone at age 48 leads Dr. O’Connor to explain why the cause of a low result matters before choosing a preparation or injection schedule. He considers health history and possible contributors, including previous steroid use, excess weight, inactivity, stress, diet, and environmental exposures.

01:40

The ABCDs™ review connects A1C, blood pressure, kidney health, cardiovascular health, blood lipids, red blood cells, and iron balance with a broader preventive assessment. After discussing mental health and screening considerations, Dr. O’Connor turns to difficulties accessing primary care and the need for patients to request appropriate evaluation.

03:10

Patients are encouraged to learn the ABCDs™ framework and work with healthcare providers to address their overall health while using testosterone. The closing remarks acknowledge overwhelmed providers and highlight the cost and insurance barriers surrounding newer medicines.

Video Summary

A 48-year-old man reports a testosterone level of 237 and asks which testosterone to use and how often to inject. Dr. Thomas O’Connor takes the question back a step: why is testosterone low, and what does the rest of the patient’s health history reveal?

Before discussing a preparation or injection schedule, Dr. O’Connor recommends a thorough evaluation with a qualified healthcare provider. Previous steroid use, the type of hypogonadism, excess weight, and individual health risks can all shape that assessment. His central message is to treat the person rather than the laboratory number.

He describes low testosterone as potentially multifactorial, discussing obesity, inactivity, stress, diet, and environmental exposures as possible contributors. He also notes that increased testing may partly explain why more cases are being identified.

The ABCDs™ framework provides a broader view of health through A1C, blood pressure, kidney health, cardiovascular health, dyslipidemia, red blood cells, and iron deposition or depletion. Dr. O’Connor extends the discussion to mental health and preventive screening, including cancer and osteoporosis considerations.

The closing discussion addresses limited access to primary care and the importance of working actively with healthcare providers. Dr. O’Connor encourages patients to understand their health assessments and request appropriate care, particularly while using testosterone. He also briefly names newer medicines, including tirzepatide, retatrutide, and semaglutide, while discussing cost and insurance barriers.

Drug Callouts

Testosterone

Testosterone is an androgen hormone that is also prescribed as replacement therapy for testosterone deficiency. Responding to a man asking about injections, Dr. O’Connor prioritizes finding the cause of his low level and understanding his health before choosing a regimen.

Tirzepatide

Tirzepatide is a medication that activates GIP and GLP-1 receptors to help regulate blood glucose and appetite. Dr. O’Connor briefly includes it among newer medicines while raising concerns about expense and insurance coverage.

Retatrutide

Retatrutide is a drug compound that activates GIP, GLP-1, and glucagon receptors. Its brief mention comes near the end of the discussion, alongside other newer medicines, without guidance on dosing or patient selection.

Semaglutide

Semaglutide is a GLP-1 receptor agonist medication that helps regulate blood glucose and appetite. The closing discussion names it as one example of newer medicines before turning to affordability and insurance barriers.

Condition Callouts

Hypogonadism

Male hypogonadism is a condition involving insufficient testosterone production, impaired sperm production, or both. Dr. O’Connor asks what type might explain the viewer’s low testosterone, making the underlying cause a priority before treatment decisions.

Obesity

Obesity is a condition characterized by excess body fat that can impair health. Excess weight and increasing abdominal fat feature prominently in Dr. O’Connor’s explanation of factors that may contribute to low testosterone.

Dyslipidemia

Dyslipidemia is an abnormal level of cholesterol or other lipids in the blood. Within the ABCDs™ framework, Dr. O’Connor places it alongside cardiovascular health as an area deserving attention beyond hormone testing.

Colorectal Cancer

Colorectal cancer is cancer that develops in the colon or rectum. Colon cancer screening appears in the broader preventive health review, without a specific test or screening interval being provided.

Prostate Cancer

Prostate cancer is cancer that develops in the prostate gland. Dr. O’Connor mentions prostate cancer screening and PSA screening when expanding the assessment beyond testosterone levels.

Breast Cancer

Breast cancer is cancer that develops in breast tissue. As the discussion broadens to women’s health, Dr. O’Connor includes breast cancer screening among the preventive considerations.

Key Takeaways

A low testosterone result is a starting point for evaluation, not enough information by itself to select a testosterone preparation or injection schedule.
Investigating low testosterone includes reviewing health history, previous steroid use, excess weight, and the possible type of hypogonadism.
Body weight, physical activity, stress, and diet belong in the assessment because low testosterone may have multiple contributing factors.
The ABCDs™ framework broadens attention beyond hormones to A1C, blood pressure, kidney health, cardiovascular health, blood lipids, red blood cells, and iron balance.
Hormone care belongs within a broader health assessment that also considers mental health and preventive screening.
Understanding relevant health assessments and requesting appropriate evaluation from healthcare providers are practical ways to participate actively in care while using testosterone.